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ABSTRACT
Racial disparities in breast cancer mortality have been
widely documented for several decades and persist despite
advances in receipt of mammography across racial groups.
This persistence leads to questions about the roles of bio-
logical, social, and health systemdeterminants of poor out-
comes. Cancer outcomes are a function not only of innate
biological factors but also of modifiable characteristics of
individual behavior and decision making as well as charac-
teristics of patient-health system interaction and the
health system itself. Attempts to explain persistent racial
disparities havemostly been limited to discussion of differ-
ences in insurance coverage, socioeconomic status, tumor
stage at diagnosis, comorbidity, and molecular subtype of
the tumor. This article summarizes existing literature ex-
ploring reasons for racial disparities in breast cancer mor-
tality, with an emphasis on treatment disparities and
opportunities for future research. Because breast cancer
care requires a high degree of multidisciplinary team col-
laboration, ensuring that guideline recommended treat-
ment (such as endocrine therapy for hormone receptor
positive patients) is received by all racial/ethnic groups is
critical and requires coordination acrossmultiple providers
and health care settings. Recognition that variation in can-
cer care quality may be correlated with race (and socioeco-
nomic and health system factors) may assist policy makers
in identifying strategies to more equally distribute clinical
expertise and health infrastructure across multiple user
populations. TheOncologist2013;18:986–993
Implications for Practice: Disparities in breast cancer outcomes result not only from racially specific tumor differences, but also
modifiable social and health system determinants, such as poor access to care and health education, lack of financial resources,
problematic patient-provider interactions, and structural barriers within the health system itself. Breast cancer care requires a
high degree ofmultidisciplinary team collaboration; therefore, ensuring that care is delivered in a coordinated, continuous, cul-
turally and socioeconomically sensitive fashion is critical to ensuring equitable receipt of guideline recommended treatments,
which in turn, will help improve outcomes across racial groups. Understanding how biological, social, and health system factors
act in concert to influenceoutcomesmayhelp clinicians, researchers, andpolicymakers to identifymore innovative strategies to
address breast cancer disparities going forward.
INTRODUCTION
Overview of Breast Cancer Treatment Disparities
Health disparities in breast cancer treatment and outcomes
have beenwidely documented for several decades. In spite of
marked advances in breast cancer survival, disparities persist
with respect to timeliness of diagnosis, receipt of treatment,
and long-termhealth outcomes. These differences have been
particularly starkbetweenwhiteandblackpatients [1–14].Al-
though breast cancer is diagnosed more often in white
women,breastcancermortality ishigheramongblackwomen
[15]. Racial trends in breast cancer incidence and mortality
also vary depending on age (Fig. 1) [16]. Specifically, younger
black women (50 years old) have a higher incidence of
breast cancer than younger white women, but around the
time of menopause, this trend reverses, and older white
womenhavehigherbreast cancer incidence [17,18]. Epidemi-
ology studies suggest that disparities in outcomes by race and
ethnicity have not improved over time, despite the fact that
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the use of screening mammography is now nearly equivalent
nationally among black and white women of all ages [19, 20].
Consequently, in the Healthy People 2010 report, the United
States Department of Health and Human Services made it
clear that elimination of health disparities was a national pri-
ority [21].
Although developing interventions to ensure high-quality
cancer treatment and optimal outcomes in the general popu-
lation is of critical importance, we should be especially con-
cerned about persistent disparities in treatment and
outcomes within vulnerable subpopulations. In many cases,
vulnerable subpopulations have not benefited equally from
novel interventions to improve cancer outcomes [22, 23].
Over time, if the quality of cancer care improves, on average,
in the general population but poor-quality care persists
among minority groups, inequities in treatment that lead to
disparate health outcomes may have been essentially ig-
nored, resulting in widening gaps in outcomes between
groups. Understanding the reasons for persistent disparities
in care for vulnerable populationsmay indicate opportunities
to improve outcomes by targetingmodifiable factors that dis-
proportionately affect vulnerable patients. In addition, basic
tenets of medical ethics compel health care providers to pay
attention to such inequities.
Factors Contributing to Breast Cancer Disparities
The picture of health disparities in breast cancer is multifac-
eted and complex. Although black women, for example, are
diagnosed at amore advanced disease stage [24], survival dif-
ferences persist betweenblacks andwhites diagnosed at sim-
ilar stages of illness, suggesting that breast cancer in black
women is fundamentally different from that inwhitewomen.
Othersupport forbiologicaldisparitycomes fromstudies find-
ing that although differences in patient stage largely disap-
pearwhenmammography receipt is controlled, blackwomen
still have significantly more high-grade breast cancers [25].
Moreover, black women are at substantially higher risk of de-
veloping“triple-negative” (hormonereceptor-andHER2-neg-
ative) breast cancer [26]. After controlling for patient and
biologic tumorcharacteristics atdiagnosis, suchas comorbidi-
ties andhormone receptorandHER2status, a clear stage-spe-
cific survival gap remains [27]. This gap has been essentially
stable over the past two decades, despite significant gains in
overall breast cancer outcomes. This gap suggests that non-
biologic factors and factors independent of stageof disease at
presentation, such as treatment differences,may also explain
a significant portion of observed outcome disparities.
Organizational, structural, socioeconomic, and sociopolit-
ical dynamics of the American health system likely contribute
to racial and ethnic health disparities andmay not be amena-
bletorapidchange. Inepidemiological terms, racialandethnic
differences in breast cancer-related morbidity and mortality
can be thought of as being produced bymultiple complemen-
tary causes [9, 14], none of which is sufficiently explanatory
alone.Possibleexplanations forenduring racial andethnicdis-
parities include biological differences in tumor behavior and
morphology [6, 26, 28–30], differences in therapeutic re-
sponse [31], patient-level psychosocial or behavioral factors
[32], socioeconomic status and access to care [9, 33, 34], and
treatment differences [8, 11, 35]. Determiningwhich of these
multifaceted factors can be adjusted to improve outcomes is
vital and requires deeper understanding of the complex rela-
tionships between biological, behavioral, and social determi-
Figure 1. Breast cancer incidence andmortality by age at diagnosis and race/ethnicity. (A): Age-specific SEER female breast cancer in-
cidence ratesby race/ethnicity, all ages, 1992–2010. (B):Age-specificUS femalebreast cancermortality ratesby race/ethnicity, all ages,
1992–2010 [16].
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nants of health. Genetic susceptibility to more aggressive
cancers, for example, cannot be changed by public health ef-
forts; however, understanding racial differences in tumor bi-
ologymay point to environment-gene interactions that could
benefit from targeted intervention. In addition, sociodemo-
graphic factors that tend to vary by race, such as access to in-
surance coverage, income, and educational attainment, may
beslowtochangeover time;however, if access tocareandso-
cioeconomic status areheld constant, there is no good reason
whyablackwomanshouldbeoffered lowerquality treatment
than awhitewomanwith the same clinical disease.
Biological Factors
As previously noted, blackwomendiagnosedwith breast can-
cer tend tohavemoreaggressive tumors andworseprognosis
than white women [17, 24, 26, 27, 36–39]. Younger black
womenarealsomore likely tohave triple-negativebreast can-
cers and less likely to have estrogen receptor (ER)-positive
cancers [26, 29, 37, 40]. Understanding the characterization
and clinical behavior of cancers with different biological fea-
tures has become increasingly important in recent years [24,
26]. Indeed,many clinicians and researcherswouldargue that
the various biological subtypes of breast cancer are so strik-
ingly different from one another that they represent entirely
different diseases andmust be treated as such [26, 36, 37, 41,
42]. Given the diversity in tumor biology in breast cancer and
the importanceofdifferential signaturesby race, understand-
ing the biological uniqueness of tumors presenting in black
women is essential [37, 43, 44].
Histological features of breast cancers also vary by race
and ethnicity [6, 28, 30, 45]. Chen and colleagues adjusted for
age, stage, socioeconomic status, bodymass index, reproduc-
tive history, insurance status, and location and found that
black breast cancer patients had greater nuclear atypia and
more necrosis compared with white women [40]. Although it
had long been recognized that blackwomenweremore likely
to have hormone receptor-negative breast cancer, recent
studies have shed additional light on this phenomenon. A se-
ries of immunohistochemical studies on tumors obtained
within the population-based Carolina Breast Cancer Study
(CBCS) found that a significantly lower proportion of black
women had the good-prognosis, hormone receptor-positive,
HER2-negative breast cancer; conversely, a higher proportion
of black women, particularly younger black women, had the
poor-prognosis, triple-negativebreastcancer.Triple-negative
disease is so called because it lacks all three of the known tar-
getable breast cancer proteins, the ERs and progesterone re-
ceptors, and the signaling pathwaymember HER2.
Higher incidence of triple-negative breast cancer has also
been observed among West African breast cancer patients
[46]. Intriguingly, theCBCSanalysisandothershavesuggested
that traditional risk factors varied by subtype [36, 47]. Some
protective factors, like early age of menarche, obesity, and
breastfeeding, were far stronger for basal-like breast cancer
than for luminal hormone receptor-positive, HER2-negative
breast cancer. Other factors actually appeared to have oppo-
site effects: Multiparity and young age at first full-term preg-
nancy, long acknowledged to be protective factors, appear to
be protective only for luminal breast cancer and rather to be
risk factors for basal-like breast cancer [36]. These studies im-
ply that lifestyle exposures may be responsible for variations
in outcomes by race in certain breast cancer subtypes; mean-
while, recent genome-wide association studies implicate
novel breast cancer risk variants inwomenofAfrican ancestry
[48].
In a review of the literature on tumor aggressiveness in
black women, Morris and Mitchell report that in addition to
these known differences in pathologically defined subtypes
and BRCA mutations, black women also have more overex-
pressionofcell-cycle regulators, suchascyclinE,p16,andp53,
and polymorphisms in nucleotide excision repair genes [45].
This large body of evidence lends considerable support to the
hypothesis that breast cancer in black women is biologically
different. It is clear, however, that biological factors cannot
explain all of the racial disparity inmorbidity andmortality [5,
36, 27, 49].
Social Factors and Screening Behaviors
Although biologic differences contribute to breast cancer dis-
parities, it is alsowidely agreed that social and behavioral fac-
tors play a large role in the racial differences observed in
breast cancer mortality. In the CBCS, after controlling for bio-
logic differences in tumor subtype, racial disparities in out-
comes not only persisted but were particularly prominent
among the good-prognosis, hormone receptor positive,
HER2-negative tumors, suggesting that social and behavioral
factors that vary by race may have been driving outcome dif-
ferences (Fig. 2) [27]. Persistent racial disparity has been
linked to underuse of screeningmammography and lack of di-
agnostic follow-up after an abnormal mammogram result [6,
49]. Use of screening mammography, however, has been
nearly equivalent among racial andethnic groups for adecade
[49, 50], and evenwhen controlling for stage at diagnosis and
insurance status, differences in mortality persist; although
secular trends in disease-specific mortality have shown im-
provements in the past 30 years, the relative difference be-
tween mortality rates for black women and non-Hispanic
women has not changed (Fig. 3) [16]. Rather, the gap appears
to bewidening.
Social factors, including poverty and financial insecurity,
lack of transportation, poor access to care, poor health liter-
acy, low educational attainment, and lack of health insurance
contribute substantially to differences in breast cancer out-
comes [5, 9, 12, 51–56]. Lower income and uninsured cancer
patients are especially sensitive to the high costs of cancer
care and may be more likely to be fromminority groups [57].
Regardless of insurance status, the hidden costs of cancer
Some protective factors, like early age of menarche,
obesity, and breastfeeding, were far stronger for
basal-like breast cancer than for luminal hormone re-
ceptor-positive, HER2-negative breast cancer. Other
factors actually appeared to have opposite effects:
Multiparity and young age at first full-term preg-
nancy, long acknowledged to be protective factors,
appear tobeprotectiveonly for luminalbreast cancer
and rather to be risk factors for basal-like breast
cancer.
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care, including transportation and the inability to work, may
beespecially burdensome to theminority cancer patient [58].
The addition of novel biologic therapies such as trastuzumab
tostandard treatment forbreast cancerhas increasedcosts to
such a point that even insured patients may face staggering
copayments and other shared costs [59, 60]. In one national
surveyof cancerpatientsand families conductedby theKaiser
Family Foundation, USA Today, and the Harvard School of
Public Health (2006), nearly one in four privately insured pa-
tients had exhausted all or most of their personal savings to
pay for cancer-related care, and 13% of cancer patients re-
ported being contacted by a collection agency demanding
payment for cancer treatment [61]. As treatment options be-
come more sophisticated and prognosis continues to im-
prove, costs associated with treatment, survivorship, and
surveillancewill become increasingly important issues to con-
sider in understanding racial variation in outcomes.
Several other patient-level social and behavioral factors
may help explain why different patients receive different
treatments and experienceworse health outcomes. These in-
clude health literacy and personal preferences [62], cognitive
and social network correlates [32], trust in thehealth care sys-
tem, and health care-seeking behavior [35, 63].
Finally, competing comorbidities, which differ by race,
also affect breast cancer screening, diagnosis, and outcomes
[14]. Higher comorbidity burden among blacks could affect
both overall survival and disease-specific survival, if care for
comorbidities competes with cancer care priorities. In addi-
tion, if functional status or mental health status is compro-
misedby comorbid conditions, thesemayalso inhibit—rather
than promote—health-seeking behaviors for cancer diagno-
ses [14].
Health System Factors
Althoughmuch researchhasbeenpublished in theareasofbi-
ological tumor variation and social and behavioral factors as
they relate to race and ethnicity-related breast cancer dispar-
ities, relatively little has beenpublished about howcharacter-
istics of the health system itself, including provider- and
facility-level factors, affect racial variation in treatment and
outcomes. Structural and organizational differences in health
servicesavailable towomencanexplain someof the racial and
ethnic disparity in breast cancer treatment and outcomes
[64–66].
Someof theprincipal structural andorganizational factors
known to affect the quality of cancer care are summarized in
Table 1. These physician- and facility-level factors have vary-
ing degrees of influence on quality of cancer care received.
Severalmaybemoreor less problematic for particular patient
subpopulations. For example, distance to care may pose a
Figure 2. Race-stratifiedKaplan-Meierplots and raceeffect estimates forbreast cancer-specificmortalityby immunohistochemical subtype
in theCarolinaBreastCancer Study, 1993–2006 [27].Abbreviations: CI, confidence interval; ER, estrogen receptor;HR,hazard ratio.
Figure 3. Age-adjusted U.S. female breast cancer-specific mor-
tality rates by race, 1975–2005 [16].
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greater barrier to care for olderwomen, given the transporta-
tion andmobility difficultiesmanyelderlywomen face [67]. In
addition, health-seeking behavior and use of health services
with certain structural and organizational characteristics
likely vary by subgroups. For example, some ethnic groups
may prefer to access health care facilities that recognize and
address language barriers by hiring translators; those health
facilities that canafford tooffer suchpatient servicesare likely
different in termsoforganizationand size fromthose facilities
thatdonotofferbilingual services. Inaddition,membership in
racial and ethnic groups may correlate with community resi-
dence,andtypeand locationofhealth facilitiesmayberelated
to sociodemographic makeup of the local user population.
Consequently, innovative care processes may be distributed
unequally. If distribution and diffusion of evidence-based in-
novations are disproportionately benefiting certain women
compared with others, differential quality of care may be ob-
served across sociodemographic groups.
Finally, patient sociodemographics could be associated
with the typesand thequalityofprovidersandhealth facilities
thatareavailable to the localuserpopulation.Blackcancerpa-
tients may have worse access to well-trained providers and
more often be treated by physicians who lack measurable
skills, board certification, and technical resources [68]. In one
study,physiciansofblackcancerpatientsmoreoftenreported
that they were unable to provide the best care to their pa-
tients, although the reasons are somewhat unclear [68].
Health services characteristics are rarely considered in
empirical analyses to confoundormodify the effect of raceon
breast cancer treatmentandoutcomes.Analyses thathave in-
cluded health system variables as covariates in addition to
race and ethnicity, such as one study using data from the Na-
tional Cancer Database [69], have generally highlighted the
importance of a few structural andorganizational variables as
potential confounders only. In this study, after controlling for
hospital teaching status, regional supply of radiation oncolo-
gists, surgical volume, and ratio of specialists to generalists in
predicting receipt of breast-conserving surgery over time,
racewas statistically nonsignificant. In addition, blackwomen
who failed to receive timely screening mammography re-
ported that they lackedphysician referralor recommendation
for the test [70].
The interactive effects of structural and organizational
variables and race and ethnicity have been explored to a
greater degree in the literature of other cancers. In prostate
cancer, black men have poorer access to health care and less
continuityofcare forscreeningand,oncediagnosed,aremore
likely tobetreatedby lowervolumesurgeons[63,71]. In rectal
cancer, black patients are more likely to be treated by low-
volume physicians and less likely to receive adjuvant therapy
[72]. In a study of advanced lung cancer patients, black pa-
tients, particularly of lower socioeconomic status, were less
likely to seeanoncology specialist andsubsequently less likely
to receive clinically recommended chemotherapy, after con-
trolling for age, sex, year of diagnosis, region, hospital teach-
ing status, and comorbidities [73].
To date, the breast cancer literature has rarely considered
the role of multiple health service organization measures ex-
plicitly on racial and ethnic disparities in treatment and out-
comes.Theexceptionsare twoSurveillanceEpidemiologyand
End Results (SEER)-Medicare studies that showed that health
system factors, including distance to care,maymodify the re-
lationship between race and ethnicity and receipt of guide-
line-recommended breast cancer treatment, including
radiation therapy and chemotherapy [65, 66]. Research sug-
gests that pinpointing system-level factors that may contrib-
ute to persistent disparities can help policy makers focus
efforts to equalize health care access and quality across di-
verse user populations.
Treatment Differences
Differences in treatment, working in parallel with race-based
biological differences, are believed to account for a large por-
tion of the variation in breast cancer outcomes, in particular,
the persistent state-specific survival gap observed between
white and black women [5]. If certain subpopulations receive
less-than-standard treatment (i.e., treatment appropriate for
the features of the cancer), differences in outcomes are likely
to result. Black women, more often than other women with
the same stage disease, fail to receive timely diagnosis and
recommended treatment for breast cancer [13, 74].
Multiple studies have documented racial disparities in al-
most every aspect of breast cancer treatment. Black and His-
panicwomenfail to receivedefinitive local therapy forcurable
breast cancers more often than whites, after adjustment for
ageandtumorcharacteristics [8]. Similarpatternsareseen for
adjuvant chemotherapyand radiotherapy,withblackandHis-
panic women failing to receive appropriate adjuvant therapy
more often than whites, even after controlling for access to a
medical oncologist [3]. Black women are four to five times
more likely to experience treatment delays longer than 60
daysandsignificantly less likely toreceivecancer-directedsur-
gery, radiation therapy after lumpectomy, and hormonal
therapy for hormone receptor-positive tumors, after control-
ling for tumor characteristics [11]. Such findings of treatment
disparities appear to be consistent across geographical areas,
having been documented in studies in Detroit, Michigan [1];
Table 1. Health systemorganizational and structural factors
affecting cancer care quality
Environmental Distance to care
Geographic location




Notification and reminder systems
Stated commitment to quality
improvement
Incentive-based systems in place
Facility type, practice setting, profit
status, and size
Institutional affiliations Cancer care organizations
Research alliances
Academic and teaching status
Provider Physician training and education
Specialist-generalist collaboration
Physician gender, age, and race
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Atlanta,Georgia [11]; and innational SEERsamples [8,66]. Ina
SEER-Medicare studyusing a compositemeasureof adequate
breast cancer that includedappropriate radiation therapy fol-
lowing breast-conserving surgery, documentation of ER sta-
tus, and surveillance mammography, black and Hispanic
womenwere significantly less likely to receive adequate care,
and thedisparity actually increasedover time [10]. Even in the
controlled setting of a large randomized clinical trial, black
womenwere significantlymore likely to have early treatment
discontinuation or delay than thewhite participants [75].
Studies examining treatment disparities have several lim-
itations that complicate attempts to determine the root
causes of differences in treatment. These include limited fol-
low-up periods in national datasets such as SEER, underre-
porting of adjuvant therapies, and limited information
regarding patient socioeconomic status and other social fac-
tors. Black womenwith breast cancer also havemore comor-
bidities than their white counterparts [1], a factor that may
influence treatment decisionmaking, and not all studies have
been able to control for this difference.
Racialdisparitiesalsoexist inaccess tocutting-edgebreast
cancer treatments,both in theclinical trial settingandas inno-
vationsmove into standard clinical practice. Blackwomen are
more reluctant to enroll in clinical trials and thus may have
pooreraccess to trial-based innovations incancercare [22,23,
76–78]. In addition, few breast cancer randomized trials ana-
lyze outcomes based on race and ethnicity because of insuffi-
cient sample size, indicating a failure to report data that may
inform disparities-focused interventions [79]. Consequently,
certain groups may be denied research-related innovations,
and this trend may continue as novel treatments move into
clinical treatment settings. Blackwomen, for example, less of-
ten receive sentinel lymph node biopsy (SLNB), a morbidity-
sparing approach to axillary lymph node staging [7, 80]. Despite
overall higher levels of uptake of SLNB between 1998 and 2005,
racial and ethnic gaps in receipt of SLNB remained largely the
sameovertime[7].Blackwomenarealsolesslikelytoreceiveany
typeof lymphnodesurgery for axillary staging [81].
Additional review articles overwhelmingly echo the findings
of thespecific empirical studieshighlightedabove [13,14]. Shav-
ers and Brown reported on several other treatment disparities
betweenracialandethnicgroups, includingdifferencesinreceipt
of biomarker testing, follow-up after diagnosis and initial treat-
ment, and surveillance mammography [13]. In addition, black
and Hispanic women suffer more often from inadequate pain
management and serious side effects of treatment [5, 14, 82].
Other authors concluded that disparities in treatment were the
result of patient- or tumor-related, provider-related, and health
system-related differences but that these factors were rarely
considered explicitly in empirical studies as acting together [14,
35].
Significant gaps remain in our understandingof treatment
disparities in breast cancer. Among themost prominent is the
use of endocrine therapy in hormone receptor-positive pa-
tients, who compose the majority of breast cancer survivors.
Although theproblemof early discontinuationandnonadher-
ence to endocrine therapy has been documented in a variety
of patient populations [83–93], little is known about differ-
ences in endocrine therapy adherence among women of dif-
ferent races. Studies have shown conflicting relationships
between race and endocrine therapy utilization among hor-
mone receptor-positive subtypes [85, 87, 88, 94]. Because the
racial gap in breast cancer survival is known to be largest
amongestrogen-sensitive subtypes inwhomprolonged treat-
ment over years is key to improving outcomes [27], and be-
cause nonadherence has been demonstrated to affect
survival outcomes [95], differences in utilization of antiestro-
gentherapiesmaywellexplainsomeportionof thedisparity in
outcomes for these patients.
Opportunities and Recommendations for
Future Research
Improving health-seeking behavior and trust in the health
care system are difficult targets for research interventions,
given the complex historical experiences of American minor-
ity groups [9, 96]. Similarly, advances in understanding ofmo-
lecular differences in breast cancer by race that will enable
individualized therapy are still on the horizon. As a starting
point, ensuring equal access to provider- and facility-level
health care resources should be a priority.
Although biologic and behavioral differences may influence
outcomes to someextent, evidence suggests thatwhenwomen
across racial and ethnic groups receive equal treatment, equal
outcomes follow[97,98].Blackpatientsareatnogreater risk for
chemotherapy-related hematologic toxicity thanwhite patients
[99], andclinical trial results suggest thatpatternsof response to
localandsystemictherapyaresimilarforblackandwhitewomen
withclinicallyequivalentdisease[75,100–102]. In lightofthisev-
idence, it is critically important that thehealth systemitself isde-
signed in such a way that all women have access to life-
prolonging cancer treatments, regardless of race, age, or
socioeconomic status.
CONCLUSION
Canceroutcomesarea functionnotonlyof innatebiological fac-
tors but also of modifiable characteristics of individual behavior
and decision making as well as characteristics of the patient-
health system interactionand thehealth system itself. Attempts
to explain persistent racial and ethnic disparities have mostly
been limited to discussion of differences in insurance coverage,
socioeconomic status, stage at diagnosis, comorbidity, andmo-
lecular subtype of the tumor. Because breast cancer care re-
quires a high degree of multidisciplinary team collaboration,
ensuring that critical guideline-recommended treatment is re-
ceived(e.g.,endocrinetherapyforER-positiveandprogesterone
receptor-positive patients) is critical and requires coordination
across multiple providers and health care settings. Recognizing
thatvariationinqualityofcancercarereceivedmaybecorrelated
with sociodemographic and health system characteristics may
Because the racial gap in breast cancer survival is
known to be largest among estrogen-sensitive sub-
types inwhomprolonged treatment over years is key
to improving outcomes, and because nonadherence
has been demonstrated to affect survival outcomes,
differences in utilization of antiestrogen therapies
maywell explain someportion of the disparity in out-
comes for these patients.
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assist policymakers in identifying strategies tomore equally dis-
tribute clinical expertise and health infrastructure across multi-
pleuserpopulations.
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